Creative Touch Permanent Makeup and Aesthetics

Deoxycholic acid is a bile acid produced endogenously in the human gut whose membrane-disrupting chemistry – originally evolved for fat emulsification in digestion – has been repurposed as an injectable fat reduction agent. When injected into subcutaneous adipose tissue, it physically lyses adipocyte membranes, causing permanent adipocyte destruction and subsequent inflammatory clearance. The result is durable: destroyed adipocytes are replaced by fibrous connective tissue rather than new fat cells, making the volume reduction from deoxycholic acid injection structurally distinct from modalities that reduce adipocyte size without destroying them. Understanding the mechanism accurately – particularly that it produces necrosis rather than apoptosis, and that its tissue selectivity is technique-dependent rather than inherent – is essential for honest clinical discussion and appropriate adverse event framing.

Deoxycholic acid is a secondary bile acid – secondary meaning it is produced not by the liver directly but by intestinal bacteria acting on primary bile acids (cholic and chenodeoxycholic acid) secreted by the liver into the gut. Its endogenous function is fat emulsification: DCA inserts between the hydrophobic lipid molecules of dietary fat aggregates, creating an interface between the fat and the surrounding aqueous environment that allows pancreatic lipases to access and hydrolyse triglycerides for absorption. ^[5]

The chemistry that makes DCA an effective emulsifier in the gut – its amphiphilic structure, with a hydrophilic and a hydrophobic face allowing it to disrupt and reorganise phospholipid arrangements – is precisely the chemistry exploited in its aesthetic application. The molecule used in Aqualyx and equivalent injectable formulations is a synthetic form structurally identical to the endogenous molecule, produced without human or animal-derived contaminants and formulated for subcutaneous injection rather than enteric delivery. ^[6]

This endogenous origin is clinically relevant beyond the biochemical context. It means the body has established metabolic pathways for processing deoxycholic acid; the injected molecule is not a foreign chemical but a compound the body recognises and can metabolise through normal bile acid recycling pathways once it clears the treatment site.

The Mechanism – Detergent-Mediated Necrosis

The mechanism of deoxycholic acid is categorically different from cryolipolysis, cavitation, or radiofrequency fat reduction – and most consumer-facing content misrepresents it. DCA does not trigger apoptosis (programmed, controlled cell death). It acts as a detergent: it inserts into and physically disrupts the phospholipid bilayer of the adipocyte cell membrane, causing membrane lysis and necrosis – uncontrolled cell death characterised by rapid membrane rupture and release of intracellular contents. ^[4]

The histological timeline following injection is well-documented and explains the clinical course precisely: ^[11]

The post-treatment inflammatory response – the swelling, heat, bruising, tenderness, and firmness that clients experience in the days following injection – is not a side effect of the treatment. It is the mechanism operating correctly. The acute inflammation is the adipocytolysis clearance process; suppressing it aggressively with anti-inflammatories during this window is mechanistically counterproductive. This is the single most important point that consumer-facing content consistently fails to communicate.

Why Adipocytes Are Preferentially Affected – The Protein-Binding Selectivity

The claim that deoxycholic acid “selectively targets fat cells” is widely repeated but mechanistically imprecise. DCA is not inherently adipocyte-selective – in vitro, it disrupts any phospholipid bilayer it contacts, regardless of cell type. The apparent in vivo selectivity arises from the differential protein environment between adipose and non-adipose tissue. ^[6]

Dermis, muscle, and vascular tissue are protein-rich environments containing albumin and other proteins that bind DCA and inactivate it before it reaches cell membranes. Subcutaneous adipose tissue is relatively protein-poor – adipocytes are primarily lipid-filled rather than protein-dense – so DCA retains its membrane-disrupting activity in this compartment rather than being bound and inactivated. ^[10]

The clinical implication is direct and significant: injection depth is the selectivity mechanism. Correct placement deep in the subcutaneous compartment deposits DCA in the protein-poor environment where selectivity operates. Superficial injection into the protein-rich dermis removes this protective mechanism – DCA is no longer inactivated before reaching cell membranes, and dermal necrosis results. Documented skin necrosis complications from injection lipolysis are predominantly technique-dependent adverse events arising from insufficient injection depth, not inherent product toxicity. This is why practitioner training, anatomical knowledge, and injection technique are not administrative requirements but mechanistic necessities. ^[8]

The Aqualyx Formulation

Aqualyx is not simply a solution of deoxycholic acid. It is a pharmaceutical formulation of deoxycholic acid complexed with a plant-derived galactose polymer matrix in an aqueous gel, buffered to physiological pH. The polymer matrix serves two functions: it slows the diffusion of DCA from the injection site, extending local tissue contact time and producing more complete adipocytolysis in the target area; and it reduces the risk of rapid lateral spread to non-target tissue that pure DCA solution would produce. ^[2]

This distinguishes Aqualyx from two other deoxycholic acid products that practitioners and clients may encounter in discussions:

Kybella (ATX-101) is the US FDA-licensed equivalent – a sodium deoxycholate solution licensed specifically for submental (chin) fat reduction only. It is not CE-marked and is not the product used in UK aesthetic practice. The active molecule is the same; the formulation differs and the licensed indication is considerably narrower. ^{[2] [8]}

Compounded PC/DCA formulations – earlier injection lipolysis practice used combinations of phosphatidylcholine (PC) and deoxycholic acid. Research has since established that DCA is the primary bioactive component; PC alone produces apoptosis via TNF-α pathway activation but does not cause adipocytolysis, and combined PC/DCA produces outcomes equivalent to DCA alone. Aqualyx is a DCA-primary formulation; the historical PC/DCA debate is largely resolved in the primary literature, though older protocol descriptions and some practitioner training may still reference PC-containing formulations. ^[6]

Permanent Adipocyte Destruction – The Clinical Significance

The durability of fat reduction from deoxycholic acid injection is mechanistically grounded in a straightforward biological fact: adipocytes cannot regenerate. Once an adipocyte is destroyed, it is not replaced by a new adipocyte – the cleared space is occupied by fibroblast-deposited connective tissue. The volume reduction from Aqualyx is therefore permanent at the cellular level, not a temporary size reduction that reverses when the stimulus is removed. ^[9]

The practical qualification is that remaining adipocytes in the treated area and adjacent areas can undergo hypertrophy – enlarging with caloric surplus – which can partially offset the volumetric reduction from adipocytolysis over time. The durability of the clinical result is therefore real and mechanistically grounded but not unconditional; it is maintained by a dietary environment that does not drive significant adipocyte hypertrophy in surrounding tissue. This is meaningfully different from stating “results last as long as you maintain your weight” – the adipocytes that were destroyed are gone permanently; what changes with weight gain is the adipocytes that were not treated.

This permanence also distinguishes Aqualyx from cryolipolysis at the mechanistic level. Cryolipolysis achieves fat layer reduction through apoptotic clearance of a proportion of adipocytes in the treated area over 8–12 weeks; the process is gradual and the result is a reduction in adipocyte number. Aqualyx achieves adipocyte destruction through immediate necrotic lysis with subsequent connective tissue replacement – a different cellular pathway producing a durable structural change in the tissue architecture.

Clinical Evidence

The evidence base for injection lipolysis with deoxycholic acid is dominated by observational studies and case series rather than randomised controlled trials, with the exception of the submental fat indication (ATX-101/Kybella) which has the strongest RCT evidence base due to FDA licensing requirements. ^[9]

Systematic review findings: A 2019 systematic review of injection lipolysis found consistent evidence of measurable fat reduction in treated areas across multiple anatomical sites, with an acceptable safety profile when administered by trained practitioners. Effect sizes and result timelines varied across studies, reflecting the sensitivity of outcomes to injection technique, concentration, treatment intervals, and anatomical site. ^[9]

Anatomical evidence distribution: Submental fat has the strongest and most consistent evidence base. Abdominal, flank, thigh, and knee fat are supported by European observational literature and practitioner case series but lack the RCT-level evidence of the submental indication. This gradient of evidence should inform the confidence with which outcomes in different anatomical areas are discussed. ^{[1] [7]}

Treatment course: Typically 4–6 sessions spaced 4–6 weeks apart, allowing the inflammatory clearance and connective tissue remodelling cycle to complete between treatments. Assessing results before the 4-week remodelling phase is complete produces an inaccurate picture of the final outcome. ^[9]

Adverse Events and Safety

The distinction between expected treatment responses and adverse events is particularly important for deoxycholic acid given that the mechanism is necrotic – the inflammatory response is substantial and expected, not a signal that something has gone wrong.

Expected and mechanism-appropriate

Swelling (oedema from acute inflammation), bruising, pain and tenderness at the injection site, warmth, and palpable firmness in the treated area in the days to weeks following treatment. These reflect the adipocytolysis and clearance process and resolve as the inflammatory phase subsides. ^[6]

Technique-dependent adverse events

• Skin necrosis: The most serious complication; arises from superficial injection into the dermis rather than deep subcutaneous placement, removing the protein-binding selectivity mechanism. Preventable with correct injection depth and anatomical knowledge. ^[8]

• Nodule formation: Firm subcutaneous nodules, typically from superficial injection or excessively concentrated product in a localised area. Documented in post-treatment case reports; management options include massage, intralesional steroid injection, or – in persistent cases – surgical excision. ^[8]

• Nerve injury: At anatomical sites with superficial nerve branches (notably the marginal mandibular nerve in submental treatment), nerve proximity must be accounted for in injection planning. Temporary sensory disturbance is documented; permanent injury is rare with appropriate technique.

Adverse events: expected vs complication

Regulatory context

Aqualyx is CE-marked for use in the UK. The US FDA has issued explicit guidance warning against unlicensed fat-dissolving injection products available outside regulated channels. Clients seeking treatment outside of licensed, trained practitioners are at documented risk from products of unknown composition and formulation. ^[3]

Contraindications and Patient Selection

Contraindications include active hepatic disease (impaired bile acid metabolism), autoimmune conditions affecting wound healing or inflammatory response, pregnancy and breastfeeding, and active infection or skin conditions at the treatment site. Clients with very low body fat, poor skin elasticity, or significant skin laxity in the treatment area require careful assessment – volume reduction without adequate skin retraction can worsen the appearance of laxity rather than improving contour. BMI is a relative rather than absolute factor; the treatment is most effective for localised fat deposits in clients at or near a healthy weight. Areas with compromised lymphatic drainage impair the macrophage-mediated clearance process and should be assessed at consultation.